LUCA Biologics
Cambridge
About LUCA Biologics
LUCA Biologics is a biotechnology company developing a new class of living medicines targeting the vaginal microbiome to impact reproductive and urogenital health. Emerging from the lab of Dr. Jacques Ravel, Primary Investigator on the vaginal microbiome division of the NIH's Human Microbiome Project, our platform takes a metagenomic and metatranscriptomic approach to the identification, screening and validation of strains with therapeutic potential. Our pipeline includes therapeutics for urinary tract infection (UTI), preterm birth (PTB), bacterial vaginosis (BV), and infertility. LUCA Biologics is a Seed Health foundry company.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $2.8M
- Funding stage: Seed
- Last round: Seed (Aug 2019)
- Website: luca.bio
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/luca-biologics-49023 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.